There is a stubborn gap at the centre of Australia's blood pressure problem. Raised blood pressure is by far the leading risk factor for preventable deaths in Australia, contributing to over 25,000 deaths annually — mainly due to stroke, heart disease, kidney disease and dementia. Yet of the estimated 6.8 million Australian adults with hypertension, roughly 3.4 million have never had their condition detected and remain unaware they are at risk. That is not a small oversight. It is a public health crisis hiding in plain sight.
Against that backdrop, a compact wristband from Swiss medical technology company Aktiia is attracting serious attention. The Hilo Band — reviewed recently by ZDNet, which found it detected hypertension that an Apple Watch had missed — promises to do something that traditional blood pressure management has never managed at scale: monitor a person's cardiovascular readings continuously, around the clock, without ever inflating a cuff.
What the device actually does
The Hilo Band uses optical sensors — a technique known as photoplethysmography, or PPG — to detect signals from the wrist, calculating blood pressure using Pulse Wave Analysis following an initial calibration with an included cuff. It tracks blood pressure and heart rate automatically about 25 times per day without requiring any action from the wearer. The device is designed to be worn continuously, including during sleep, and can run for two weeks on a single battery charge.
A companion app syncs with the band via Bluetooth and shows how blood pressure changes throughout the day and night, with trends linked to activity, meals, stress, sleep and medication. The data can be exported as a report for sharing with a GP or specialist — a feature that users and some clinicians have found genuinely useful, particularly for people managing hypertension between appointments.
The Hilo Band is a product of the Swiss company Aktiia and is expected to cost around AUD $385. The device has received regulatory go-aheads in Canada, Australia and Saudi Arabia, in addition to its CE Mark in Europe, and in July 2025 became the first cuffless blood pressure monitor to receive FDA 510(k) clearance for over-the-counter use in the United States. That regulatory milestone is significant: it means the technology has been assessed not only for safety but for use by consumers without a prescription.
The clinical evidence: promising, but layered
The research shows a device with genuine clinical backing, though it is important to distinguish between what the trials demonstrate and what they do not. In one study, the calibration cuff showed readings within 1.3 mmHg for systolic and 0.2 mmHg for diastolic pressure compared to a mercury sphygmomanometer. A month-long trial confirmed the band's accuracy in the sitting position, with mean differences of less than 0.5 mmHg for both systolic and diastolic readings. A comparison with ambulatory blood pressure monitoring found no significant differences in daytime readings, with the Hilo Band accurately identifying 79 per cent of nocturnal blood pressure dippers — a key indicator of cardiovascular health.
Before drawing conclusions, several caveats apply. The key studies cited by Aktiia involved only small groups of test subjects — 91 and 52 people respectively — which limits how confidently their findings can be generalised. Additionally, the device's ISO certification covers non-continuous blood pressure measurements, with the relevant extension standard for continuous non-invasive monitoring not yet held. These are not disqualifying limitations, but they are worth understanding before making clinical decisions based on the data.
What the data actually tells us is that cuffless wearables as a category remain genuinely promising but unevenly validated. A December 2025 scientific statement from the American Heart Association found that cuffless devices show great promise as alternatives to traditional arm-cuff monitors, but are not yet proven accurate enough to diagnose high blood pressure or guide treatment decisions. A separate systematic review published in late 2025 found that currently available wearable cuffless devices are not yet reliable for nighttime blood pressure assessment — a critical limitation given the importance of nocturnal blood pressure in cardiovascular risk stratification.
The gap cuffless monitoring is trying to fill
To understand the Hilo Band's appeal, it helps to appreciate the real limits of conventional monitoring. A GP's surgery reading captures one moment, often under conditions that themselves elevate blood pressure. Traditional cuff-based methods share a fundamental drawback: they only provide a snapshot of blood pressure rather than continuous readings throughout the day and night. Intermittent measurement is easily affected by external factors — including the patient's mood during the test — which can cause what clinicians call white coat hypertension, where readings are elevated in a medical environment but normal in everyday life.
Wearable devices are expected to dramatically change the quality of detection and management of hypertension by increasing the number of measurements taken in different conditions, allowing more accurate detection of conditions that have a negative impact on cardiovascular prognosis, such as masked hypertension and abnormal blood pressure variability. That is a clinically significant shift. Strong evidence suggests that nighttime blood pressure is more strongly associated with mortality than daytime, home, or office readings — precisely the period when traditional monitoring is least practical.
The clinical significance here is not that a wearable can replace a cuff. It is that continuous data, gathered passively over weeks, can reveal patterns that a handful of clinic readings never could. The capability to monitor blood pressure through the day and overnight has the potential to unlock powerful insights for those with high blood pressure, and can provide clarity to those in pre-hypertension ranges who are likely to move in and out of normal range across the day.
Privacy, cost, and the subscription question
The Hilo Band is not without legitimate consumer concerns. Some additional functions are only available behind a paywall, and the device's data is processed exclusively in the cloud — a detail that deserves scrutiny at a time when health data privacy is under increasing regulatory and public attention. The Office of the Australian Information Commissioner classifies health information as sensitive data under the Privacy Act, and consumers should understand where their continuous cardiovascular readings are stored and who can access them.
The subscription model has drawn criticism from some users, who argue that paying an ongoing fee to access one's own health data is unreasonable on top of a device that already costs roughly AUD $385. These are fair commercial grievances. At the same time, the cost of the Hilo Band compares reasonably with ambulatory blood pressure monitoring services in the private health system, and the ability to share export-ready reports with a GP has been cited by users as a tangible clinical benefit.
A tool for monitoring, not a substitute for medicine
Australia's National Hypertension Taskforce, a partnership between the Australian Cardiovascular Alliance and Hypertension Australia, has set an ambitious goal: improving the nation's blood pressure control rates from 32 per cent to 70 per cent by 2030. Of the 6.8 million Australians with hypertension, about 3.4 million have not had their high blood pressure values detected and are unaware of their condition, and so are not receiving appropriate treatment. The question is whether a consumer wearable, even a well-validated one, can meaningfully shift those numbers.
The honest answer is: possibly, at the margins. Devices like the Hilo Band are unlikely to replace population screening campaigns or GP-led detection. What they can do is give motivated individuals, particularly those already managing cardiovascular risk, far richer data than they have ever had before. The Hilo Band requires calibration using an included cuff, and the system is not intended to make diagnoses. Data should always be used in consultation with a healthcare provider. That caveat from the manufacturer itself is the right framing.
What patients need to know is this: the Hilo Band appears to be a genuinely useful monitoring tool, with meaningful clinical validation behind it and regulatory clearance in Australia. Its strength lies in trend detection and long-term pattern recognition, not in providing single readings to act on unilaterally. Used alongside regular GP visits, shared openly with a treating doctor, and understood as a supplement to rather than a replacement for clinical care, it represents a reasonable option for Australians with known or suspected cardiovascular risk. The technology is real. The promise is real. The limitations are also real, and ignoring them would be a clinical mistake.